Karbe Frank Insider Trades

Insider Trading History

Track insider trading activity for Karbe Frank. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Phathom Pharmaceuticals
Phathom Pharmaceuticals PHAT
Director
Holding Value $924k 91,622 shares
Last Trade
May 19, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$275k 24,122 shares
$11.40
$10.09
Cidara Therapeutics
Cidara Therapeutics CDTX
Chief Financial Officer
Holding Value $0 0 shares
Last Trade
Jan 07, 2026 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$9.55M 43,125 shares
$221.50
$221.38
Cidara Therapeutics
Cidara Therapeutics CDTX
Chief Financial Officer
Holding Value $9.55M 43,125 shares
Last Trade
Jan 07, 2026 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$1.67M 7,526 shares
$221.50
$221.38
Cidara Therapeutics
Cidara Therapeutics CDTX
Chief Financial Officer
Holding Value $0 0 shares
Last Trade
Jan 07, 2026 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$25.5M 115,000 shares
$221.38
$221.38
Cidara Therapeutics
Cidara Therapeutics CDTX
Chief Financial Officer
Holding Value $11.2M 50,562 shares
Last Trade
Dec 10, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$1.6M 7,290 shares
$219.60
$221.38
Phathom Pharmaceuticals
Phathom Pharmaceuticals PHAT
Director
Holding Value $681k 67,500 shares
Last Trade
Jun 03, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$86.6k 17,500 shares
$4.95
$10.09
Cidara Therapeutics
Cidara Therapeutics CDTX
Chief Financial Officer
Holding Value $25.5M 115,000 shares
Last Trade
Feb 24, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.36M 115,000 shares
$20.50
$221.38
Phathom Pharmaceuticals
Phathom Pharmaceuticals PHAT
Director
Holding Value $575k 57,000 shares
Last Trade
Dec 13, 2024 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$99.1k 12,500 shares
$7.93
$10.09
Phathom Pharmaceuticals
Phathom Pharmaceuticals PHAT
Director
Holding Value $449k 44,500 shares
Last Trade
May 29, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$254k 25,000 shares
$10.16
$10.09
Phathom Pharmaceuticals
Phathom Pharmaceuticals PHAT
Director
Holding Value $197k 19,500 shares
Last Trade
May 23, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$108k 10,500 shares
$10.30
$10.09
Phathom Pharmaceuticals
Phathom Pharmaceuticals PHAT
Director
Holding Value $177k 17,500 shares
Last Trade
May 23, 2024 Sale (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$180k 17,500 shares
$10.30
$10.09
Better Therapeutics
Better Therapeutics MCAD
Chief Executive Officer
Holding Value $5.49M 526,516 shares
Last Trade
Dec 18, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$652k 62,500 shares
$10.43
$10.43
Better Therapeutics
Better Therapeutics BTTX
Chief Executive Officer
Holding Value $52.7 526,516 shares
Last Trade
Dec 18, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$14.5k 62,500 shares
$0.23
$0.00
Better Therapeutics- Tradeable Rights - March 2021
Better Therapeutics- Tradeable Rights - March 2021 MCADR
Chief Executive Officer
Holding Value $542k 526,516 shares
Last Trade
Dec 18, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$64.4k 62,500 shares
$1.03
$1.03
Mountain Crest Acquisition II - Units (1 Ord Share & 1 Right )
Mountain Crest Acquisition II - Units (1 Ord Share & 1 Right ) MCADU
Chief Executive Officer
Holding Value $6.08M 526,516 shares
Last Trade
Dec 18, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$721k 62,500 shares
$11.54
$11.54
Better Therapeutics- Tradeable Rights - March 2021
Better Therapeutics- Tradeable Rights - March 2021 MCADR
Chief Executive Officer
Holding Value $442k 429,429 shares
Last Trade
Jul 27, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$141k 137,005 shares
$1.03
$1.03
Better Therapeutics
Better Therapeutics BTTX
Chief Executive Officer
Holding Value $42.9 429,429 shares
Last Trade
Jul 27, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$84.9k 137,005 shares
$0.62
$0.00
Mountain Crest Acquisition II - Units (1 Ord Share & 1 Right )
Mountain Crest Acquisition II - Units (1 Ord Share & 1 Right ) MCADU
Chief Executive Officer
Holding Value $4.96M 429,429 shares
Last Trade
Jul 27, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$1.58M 137,005 shares
$11.54
$11.54
Better Therapeutics
Better Therapeutics MCAD
Chief Executive Officer
Holding Value $4.48M 429,429 shares
Last Trade
Jul 27, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$1.43M 137,005 shares
$10.43
$10.43
Phathom Pharmaceuticals
Phathom Pharmaceuticals PHAT
Director
Holding Value $151k 15,000 shares
Last Trade
May 25, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$176k 15,000 shares
$11.72
$10.09

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up